Forest Labs dumps failed stroke drug program

Faced with the Phase III failure of Desmoteplase for stroke in June, Forest Laboratories has bailed on its development partnership with Paion. Paion's other unlucky licensee, a troubled Lundbeck, said two months ago that the late-stage study revealed no statistically significant difference between the way Desmoteplase patients responded when compared to a group taking a placebo. Paion, for its part, says it is evaluating other options while Lundbeck has yet to announce its decision pending a full analysis of the data. Forest's departure does carry some benefits, though, as it pays out €4.3 million to cover research and development costs.

- read the release for more

Related Articles:
Forest buys Cerexa in $480M deal. Report
Forest halts enrollment as researchers study safety signal. Report
Forest to pay Mylan $75M for nebivolol rights. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.